Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480060/805-50-25-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-2

Name:	us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Investments (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended	9 Months Ended
Investments (Details) - USD ($) $ in Millions	Jan. 31, 2026	Jun. 30, 2025	Sep. 30, 2026
Vaporox Agreement
Asset Acquisition [Line Items]
Contingent consideration		$ 2.0
Asset acquisition, fair value			$ 2.1
Regen Lab USA LLC
Asset Acquisition [Line Items]
Contingent consideration	$ 5.0		$ 0.0
Up-front cash payment	$ 5.0